S35 Challenge of -Omics in Clinical Decision Making

Program: Symposia
Clinical/Translational Session
Saturday, April 2, 2016: 4:45 PM-6:15 PM
Room 258 (BCEC)
Chair:
James A Fagin, MD, Memorial Sloan Kettering Cancer Center, New York, NY

Nothing to Disclose: JAF
4:45 PM
James Michael Rae, PhD, University of Michigan, Ann Arbor, MI
Nothing to Disclose: JMR
5:15 PM
Tobias Else, MD, Department of Internal Medicine, Division of Metabolism, Endocrinology & Diabetes, University of Michigan, Ann Arbor, MI
Nothing to Disclose: TE
5:45 PM
Gordon B. Mills, MD, PhD, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX
Disclosures:
GBM: Consultant, Astra Zeneca, Advisory Group Member, Novartis Pharmaceuticals.
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire